• Metan G, Çiftçioğlu A, Saba R, Kılıç AU, Özdemir K, Çağ Y, Ünal DK, Aksoy F, Berk H, Mert G, Tunçcan ÖG, Tombak A, Balkan İİ, Çavuş SA, Kandemir B, Mutlu B, İnkaya AÇ, Kaynar L, Atay MH, Dursun FE, Saydam G, Ünsal Y, Sarı SF, Akan H; Study group. Antifungal Prophylaxis and Treatment of Breakthrough Invasive Fungal Diseases in High-Risk Hematology Patients.A Prospective Observational Multicenter Study. Indian J Hematol Blood Transfus 2025 Jan;41(1):75-88. doi: 10.1007/s12288-024-01790-2.

            https://pubmed.ncbi.nlm.nih.gov/39917507/

• Kara E, Metan G, Gülmez D, Arikan-Akdagli S. The impact of the COVID-19 on the antifungal consumption and antifungal resistance in Candida species isolated from the blood cultures of critically ill patients in intensive care units. Med Mycol 2025 Jan 25;63(2):myaf002. doi: 10.1093/mmy/myaf002.

            https://pubmed.ncbi.nlm.nih.gov/39814570/

• Karadogan E, Sertcelik A, Dizman GT, Uzar H, Hazirolan G, Cakir B, Metan G. A scoring system to predict resistance to ceftolozane/tazobactam in respiratory isolates of Pseudomonas aeruginosa. J Antimicrob Chemother 2025 Mar 3;80(3):788-796. doi: 10.1093/jac/dkae476.

           https://pubmed.ncbi.nlm.nih.gov/39811889/

• Aslan AT, Kara E, Köksal G, Bilir Y, Saraçoğlu KT, Eser F, Güner R, Alkan S, D'Avino A, Escudero-Sanchez R, Kutluca K, Kaya SY, Saltoğlu N, Loiacono L, Coladonato S, Del Giacomo P, Cascio A, Pallotto C, Francisci D, Öztürk B, Pınar A, Dağ O, Harris PNA, Paterson DL, Akova M. Comparison of piperacillin-tazobactam and vancomycin (TZP-VAN) with piperacillin-tazobactam and teicoplanin (TZP-TEI) for the risk of acute kidney injury (CONCOMITANT): A prospective observational, multinational, multi-centre cohort study. Int J Antimicrob Agents 2025 Mar;65(3):107446. doi: 10.1016/j.ijantimicag.2025.107446.

           https://pubmed.ncbi.nlm.nih.gov/39826571/

• Righi E, Yahav D, Nasim A, Akova M, Barac A, Scudeller L, Nagavci B, Armellini M, Zanchi C, Shirin N, Tunali V, Paño-Pardo JR, Rodríguez-Baño J, Jamrozik E; ESCMID OPENING Project Group. Incorporating ethics into infectious disease clinical practice guidelines. Clin Microbiol Infect 2025 Jan 17:S1198-743X(25)00013-8. xdoi: 10.1016/j.cmi.2025.01.008.

           https://pubmed.ncbi.nlm.nih.gov/39827993/

• Moreno-Mellado E, Aslan AT, Akova M, León E, Merchante N, Vinuesa D, Moral-Escudero E, Sadyrbaeva-Dolgova S, López-Cárdenas S, Cano-Yuste Á, Rinaldi M, Núñez-Núñez M, Giannella M, Sojo-Dorado J, Antolí-Royo AC, Chacón N, Merino-Bohórquez V, Portillo I, Rodríguez-Baño J, Docobo-Pérez F, Gutiérrez-Gutiérrez B; FOSFOMIC team. Effectiveness and tolerability of intravenous fosfomycin in treating complicated urinary tract infections caused by Escherichia coli: a prospective cohort study from the FOSFOMIC project. Clin Microbiol Infect 2025 Jan 18:S1198-743X(25)00012-6. doi: 10.1016/j.cmi.2025.01.007.

           https://pubmed.ncbi.nlm.nih.gov/39832652/